Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers

Gate2Brain

The solution

Gate2Brain
Technology

Gate2Brain (GB2) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

Read more

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Technology

Gate2Brain (G2B) has a proprietary novel technology platform for the delivery of therapeutics across biological barriers.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers.
We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Therapeutic
Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof-of-concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of:

Rare illnesses
Pediatric patients
Oncologic diseases

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.

  • Gate2Brain
  • Gate2Brain
  • Gate2Brain

News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

Winner of the Innovator’s Pitch Challenge Award at RESI Europe 2024

,
At Gate2Brain, we are thrilled to announce that we have been granted the Innovator's Pitch Challenge…

Fortifying CDMO Partnerships Elevating GMP Protocols

,
Gate2Brain's recent journey to India was transformative, significantly enhancing our collaboration with…

Andrés Morales La Madrid – Meet the Team

, ,
Recently, a new member joined our team. We're so grateful to have such an awesome crew!! It’s a pleasure…

Impuls Biomedicine – IRB

,
The Barcelona Institute for Research in Biomedicine recently released a video highlighting Gate2Brain…

G2B awarded with the Talent Prize 2023

,
We are thrilled to announce that our CEO, Meritxell Teixido, has been awarded the Talent Prize 2023 by…

Exploring Opportunities: Building Bridges with Japan’s Investment Landscape

In today's interconnected world, navigating global markets is paramount for growth and innovation. Some…

Hospital Connection

On Wednesday, Helena Castillo Ecija PhD, MBA, our Preclinical and Clinical Project Manager, attended…

Marina Plaza – Meet the Team

, , ,
https://youtu.be/CscybYeYWEE?si=gA5l5cjToqGW-wwv  

Meritxell Teixidó, one of the 20 recipients of the Jump Startup for Women in Deeptech program

Foment and the Consulate General of the United States presented the 20 entrepreneurs selected with the…
1
2
Gate2Brain
1

Making therapies a reality for patients by addressing unmet medical needs.

2

Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain